Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Chief Accounting Officer | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,366 |
Ending reported balance
After 2026-03-02 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-02-27 · Exercise / conversion · Acquired 7,500 · Balance 26,068 F1: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. Row 2 · 2026-02-27 · Tax withholding · Disposed 3,262 · Balance 22,806 F2: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026. F3: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Row 3 · 2026-02-27 · Exercise / conversion · Acquired 550 · Balance 23,356 F4: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. Row 4 · 2026-02-27 · Tax withholding · Disposed 240 · Balance 23,116 F5: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026. F3: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Row 5 · 2026-03-02 · Sale · Disposed 750 · Balance 22,366 F6: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Exercise / conversion · Disposed 7,500 · Balance 0 F1: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,650 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Exercise / conversion · Disposed 550 · Balance 1,650 F4: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,442 |
Reported balance
After 2026-02-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-27 · Grant · Acquired 5,442 · Balance 5,442 F8: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F9: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. F10: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $275.64 · Expires 2036-02-26 | Direct | 13,575 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Grant · Acquired 13,575 · Balance 13,575 F7: The stock options vest in four equal annual installments beginning on February 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.
F2: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.
F3: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.
F4: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.
F5: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.
F6: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.
F7: The stock options vest in four equal annual installments beginning on February 27, 2027.
F8: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
F9: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
F10: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 750 | $267.60 | $200,700.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 5 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,366 F6 · shares: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 5,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · derivative · entry 9 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,442 Underlying: Common Stock · 5,442 shares Expires not disclosed F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F9 · shares: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. F10 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. F10 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 13,575 | $0.00 Strike: $275.64 | $0.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · derivative · entry 8 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,575 Underlying: Common Stock · 13,575 shares Expires 2036-02-26 F7 · derivative.exercise_date: The stock options vest in four equal annual installments beginning on February 27, 2027. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionRestricted Stock Units · Derivative | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · derivative · entry 7 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,650 Underlying: Common Stock · 550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. F4 · derivative.exercise_date: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. F4 · derivative.expiration_date: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · derivative · entry 6 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. F1 · derivative.exercise_date: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. F1 · derivative.expiration_date: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 240 | $275.64 | $66,153.60 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 4 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,116 F5 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 3 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,262 | $275.64 | $899,137.68 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 2 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,806 F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-26-000002 · wk-form4_1772580832.xml · nonDerivative · entry 1 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $63.55 | $0.00 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · derivative · entry 10 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F10 · derivative.exercise_date: The options vested ratably over a four-year period beginning on February 28, 2022. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GiftCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 9 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,568 F9 · kind: Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 96 | $277.88 | $26,676.48 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 8 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,318 F8 · price: The transaction was executed in a single trade. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 400 | $275.68 | $110,272.00 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 7 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,414 F7 · price: The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 552 | $274.64 | $151,600.62 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 6 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,814 F6 · price: The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 928 | $273.71 | $254,000.56 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 5 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,366 F5 · price: The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,824 | $272.51 | $769,562.31 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 4 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,294 F4 · price: The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,700 | $271.66 | $1,548,477.39 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 3 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,118 F3 · price: The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,000 | $270.56 | $541,115.80 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 2 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,818 F2 · price: The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 19:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 12,500 | $63.55 | $794,375.00 |
DisclosureSEC source: 0001711279-26-000011 · wk-form4_1770854928.xml · nonDerivative · entry 1 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · derivative · entry 10 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F12 · shares: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. F13 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026. F13 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $179.25 | $0.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · derivative · entry 9 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-02-28 F10 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2026. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · derivative · entry 8 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: 15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025. F8 · derivative.exercise_date: 15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025. F8 · derivative.expiration_date: 15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · derivative · entry 7 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025. F5 · derivative.exercise_date: 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025. F5 · derivative.expiration_date: 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,471 | $179.25 | $622,176.75 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · nonDerivative · entry 6 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,318 F9 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 PSUs on February 28, 2025. F7 · price: The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · nonDerivative · entry 5 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: 15,000 PSUs were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2025. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,315 | $179.25 | $414,963.75 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · nonDerivative · entry 4 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,289 F6 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2025. F7 · price: The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 28, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · nonDerivative · entry 3 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024, and the remaining 5,000 PSUs vested on February 28, 2025. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 750 | $175.22 | $131,415.00 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · nonDerivative · entry 2 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,604 F3 · shares: The sale of the shares of the Company's common stock reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 18, 2024 and will terminate on the earlier of August 20, 2025 or the date all trades are executed or expire under the Rule 10b5-1 trading plan. F4 · price: The transaction was executed in multiple lots at the same price, $175.22. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 19:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,268 | $176.39 | $400,052.52 |
DisclosureSEC source: 0001801385-25-000002 · wk-form4_1740787298.xml · nonDerivative · entry 1 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,354 F1 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2025. 19,600 Restricted Stock Awards ("RSAs) were granted on February 26, 2021, to the Reporting Person. Each RSA represented a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSAs vested in four equal annual installments beginning on February 26, 2022. F2 · price: The closing price on February 26, 2025 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantPerformance Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · derivative · entry 21 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F15 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. F16 · shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting. F17 · derivative.exercise_date: If any applicable portion of the performance criteria have been achieved, the PSU award shall vest in two equal annual installments (February 28, 2025 and February 28, 2026). F18 · derivative.expiration_date: If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · derivative · entry 20 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_price: Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024. F14 · derivative.exercise_date: The Performance Stock Units vest ratably over a two-year period with the first installment vesting on February 28, 2024. F14 · derivative.expiration_date: The Performance Stock Units vest ratably over a two-year period with the first installment vesting on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $63.55 | $0.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · derivative · entry 19 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F12 · derivative.exercise_date: 50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,314 | $163.08 | $377,367.12 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 18 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,622 F10 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,000 PSUs on February 28, 2024. F11 · price: The closing price on February 28, 2024 of the Company's common stock on NASDAQ. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 17 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · shares: 10,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. All of the performance criteria were achieved and one-half of the PSUs granted, or 5,000 PSUs, vested on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 90 | $172.23 | $15,500.70 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 16 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 90 | $63.55 | $5,719.50 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 15 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 117 | $169.82 | $19,869.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 14 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F8 · price: The transaction was executed in multiple trades ranging from $169.790 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 117 | $63.55 | $7,435.35 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 13 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,216 | $169.09 | $205,619.03 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 12 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F7 · price: The transaction was executed in multiple trades ranging from $168.680 to $169.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 1,216 | $63.55 | $77,276.80 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 11 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 300 | $167.85 | $50,355.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 10 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F6 · price: The transaction was executed in multiple trades ranging from$167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 300 | $63.55 | $19,065.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 9 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 300 | $166.06 | $49,818.99 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 8 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F5 · price: The transaction was executed in multiple trades ranging from $165.980 to $166.110. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 300 | $63.55 | $19,065.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 7 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,429 | $164.81 | $235,509.92 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 6 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $164.300 to $165.220. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 1,429 | $63.55 | $90,812.95 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 5 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 900 | $163.68 | $147,308.04 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 4 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $163.190 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 900 | $63.55 | $57,195.00 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 3 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 648 | $162.71 | $105,436.21 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 2 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $162.155 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 648 | $63.55 | $41,180.40 |
DisclosureSEC source: 0001801385-24-000011 · wk-form4_1709342394.xml · nonDerivative · entry 1 ROMANO KATHRYN · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $150.00 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.